CEA TCB is a novel IgG-based T Cell Bispecific antibody for the treatment of CEA-expressing solid tumors currently in Phase 1 clinical trials (NCT02324257). Its format incorporates bivalent binding to CEA, a head-to-tail fusion of CEA and CD3e binding Fab domains and an engineered Fc region with completely abolished binding to FcγRs and C1q. The study provides novel mechanistic insights into the activity and mode of action of CEA TCB.CEA TCB activity was characterized on 110 cell lines in vitro and in xenograft tumor models in vivo using NOG mice engrafted with human PBMCs.Simultaneous binding of CEA TCB to tumor and T cells leads to formation of immunological synapses, T cell activation, secretion of cytotoxic granules and tumor cell lysis...
BACKGROUND & AIMS: New treatment approaches are needed for patients with pancreatic adenocarcinoma. ...
As a breakthrough immunotherapy, T cell bispecific antibodies (T-BsAbs) are a promising antibody the...
BackgroundSensitive antibody-based tumor targeting has the potential not only to image metastatic an...
CEA TCB is a novel IgG-based T Cell Bispecific antibody for the treatment of CEA-expressing solid tu...
PURPOSE CEA TCB (RG7802, RO6958688) is a novel T-cell bispecific antibody, engaging CD3ε upon bindin...
Abstract Cancer immunotherapy is the most exciting advancement in cancer therapy. Similar to immune ...
Abstract Background The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Ant...
Chimeric antigen receptor engineered T cell (CAR-T) therapy has high therapeutic efficacy against bl...
In clinical trials a low affinity monclonal antibody (17.1A) to Ep-CAM, a tumour associated antigen ...
Bispecific antibodies that engage immune cells to kill cancer cells have been actively studied in ca...
PURPOSE: The aim of these studies was to develop a pretargeting strategy for CEA-expressing cancers ...
Most colorectal cancers (CRCs) do not respond to treatment with immune-checkpoint-inhibitors due to ...
Purpose: Genetically engineered T cells are powerful anticancer treatments but are limited by safety...
Background: Sensitive antibody-based tumor targeting has the potential not only to image metastatic ...
Background: The role of Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) as a rec...
BACKGROUND & AIMS: New treatment approaches are needed for patients with pancreatic adenocarcinoma. ...
As a breakthrough immunotherapy, T cell bispecific antibodies (T-BsAbs) are a promising antibody the...
BackgroundSensitive antibody-based tumor targeting has the potential not only to image metastatic an...
CEA TCB is a novel IgG-based T Cell Bispecific antibody for the treatment of CEA-expressing solid tu...
PURPOSE CEA TCB (RG7802, RO6958688) is a novel T-cell bispecific antibody, engaging CD3ε upon bindin...
Abstract Cancer immunotherapy is the most exciting advancement in cancer therapy. Similar to immune ...
Abstract Background The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Ant...
Chimeric antigen receptor engineered T cell (CAR-T) therapy has high therapeutic efficacy against bl...
In clinical trials a low affinity monclonal antibody (17.1A) to Ep-CAM, a tumour associated antigen ...
Bispecific antibodies that engage immune cells to kill cancer cells have been actively studied in ca...
PURPOSE: The aim of these studies was to develop a pretargeting strategy for CEA-expressing cancers ...
Most colorectal cancers (CRCs) do not respond to treatment with immune-checkpoint-inhibitors due to ...
Purpose: Genetically engineered T cells are powerful anticancer treatments but are limited by safety...
Background: Sensitive antibody-based tumor targeting has the potential not only to image metastatic ...
Background: The role of Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) as a rec...
BACKGROUND & AIMS: New treatment approaches are needed for patients with pancreatic adenocarcinoma. ...
As a breakthrough immunotherapy, T cell bispecific antibodies (T-BsAbs) are a promising antibody the...
BackgroundSensitive antibody-based tumor targeting has the potential not only to image metastatic an...